219 related articles for article (PubMed ID: 37091880)
1. Intersection of Inorganic Chemistry and Nanotechnology for the Creation of New Cancer Therapies.
Shah AS; Surnar B; Kolishetti N; Dhar S
Acc Mater Res; 2022 Mar; 3(3):283-296. PubMed ID: 37091880
[TBL] [Abstract][Full Text] [Related]
2. Platin-
Banik B; Ashokan A; Choi JH; Surnar B; Dhar S
Dalton Trans; 2023 Mar; 52(12):3575-3585. PubMed ID: 36723189
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of nanoparticle delivered cisplatin in beagles.
Feldhaeusser B; Platt SR; Marrache S; Kolishetti N; Pathak RK; Montgomery DJ; Reno LR; Howerth E; Dhar S
Nanoscale; 2015 Sep; 7(33):13822-30. PubMed ID: 26234400
[TBL] [Abstract][Full Text] [Related]
4. Emerging platinum(iv) prodrugs to combat cisplatin resistance: from isolated cancer cells to tumor microenvironment.
Wang Z; Deng Z; Zhu G
Dalton Trans; 2019 Feb; 48(8):2536-2544. PubMed ID: 30633263
[TBL] [Abstract][Full Text] [Related]
5. The prodrug platin-A: simultaneous release of cisplatin and aspirin.
Pathak RK; Marrache S; Choi JH; Berding TB; Dhar S
Angew Chem Int Ed Engl; 2014 Feb; 53(7):1963-7. PubMed ID: 24453035
[TBL] [Abstract][Full Text] [Related]
6. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles.
Dhar S; Gu FX; Langer R; Farokhzad OC; Lippard SJ
Proc Natl Acad Sci U S A; 2008 Nov; 105(45):17356-61. PubMed ID: 18978032
[TBL] [Abstract][Full Text] [Related]
7. Detouring of cisplatin to access mitochondrial genome for overcoming resistance.
Marrache S; Pathak RK; Dhar S
Proc Natl Acad Sci U S A; 2014 Jul; 111(29):10444-9. PubMed ID: 25002500
[TBL] [Abstract][Full Text] [Related]
8. A Prodrug of Two Approved Drugs, Cisplatin and Chlorambucil, for Chemo War Against Cancer.
Pathak RK; Wen R; Kolishetti N; Dhar S
Mol Cancer Ther; 2017 Apr; 16(4):625-636. PubMed ID: 28148716
[TBL] [Abstract][Full Text] [Related]
9. The Platin-X series: activation, targeting, and delivery.
Basu U; Banik B; Wen R; Pathak RK; Dhar S
Dalton Trans; 2016 Aug; 45(33):12992-3004. PubMed ID: 27493131
[TBL] [Abstract][Full Text] [Related]
10. Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo.
Dhar S; Kolishetti N; Lippard SJ; Farokhzad OC
Proc Natl Acad Sci U S A; 2011 Feb; 108(5):1850-5. PubMed ID: 21233423
[TBL] [Abstract][Full Text] [Related]
11. Precisely Assembled Nanoparticles against Cisplatin Resistance via Cancer-Specific Targeting of Mitochondria and Imaging-Guided Chemo-Photothermal Therapy.
Yang GG; Pan ZY; Zhang DY; Cao Q; Ji LN; Mao ZW
ACS Appl Mater Interfaces; 2020 Sep; 12(39):43444-43455. PubMed ID: 32883070
[TBL] [Abstract][Full Text] [Related]
12. Reduction-sensitive platinum (IV)-prodrug nano-sensitizer with an ultra-high drug loading for efficient chemo-radiotherapy of Pt-resistant cervical cancer in vivo.
Luo K; Guo W; Yu Y; Xu S; Zhou M; Xiang K; Niu K; Zhu X; Zhu G; An Z; Yu Q; Gan Z
J Control Release; 2020 Oct; 326():25-37. PubMed ID: 32531414
[TBL] [Abstract][Full Text] [Related]
13. Glutathione-Responsive Prodrug Nanoparticles for Effective Drug Delivery and Cancer Therapy.
Ling X; Tu J; Wang J; Shajii A; Kong N; Feng C; Zhang Y; Yu M; Xie T; Bharwani Z; Aljaeid BM; Shi B; Tao W; Farokhzad OC
ACS Nano; 2019 Jan; 13(1):357-370. PubMed ID: 30485068
[TBL] [Abstract][Full Text] [Related]
14. Immuno-chemotherapeutic platinum(IV) prodrugs of cisplatin as multimodal anticancer agents.
Wong DY; Yeo CH; Ang WH
Angew Chem Int Ed Engl; 2014 Jun; 53(26):6752-6. PubMed ID: 24844571
[TBL] [Abstract][Full Text] [Related]
15. Engineering liposomal nanoparticles of cholesterol-tethered amphiphilic Pt(iv) prodrugs with prolonged circulation time in blood.
Datta P; Bang S; Yue Z; Beach T; Stilgenbauer M; Wang H; Bowers DJ; Kurokawa M; Xiao H; Zheng YR
Dalton Trans; 2020 Jun; 49(24):8107-8113. PubMed ID: 32490446
[TBL] [Abstract][Full Text] [Related]
16. Unique Use of Alkylation for Chemo-Redox Activity by a Pt(IV) Prodrug.
Pathak RK; Dhar S
Chemistry; 2016 Feb; 22(9):3029-36. PubMed ID: 26807548
[TBL] [Abstract][Full Text] [Related]
17. Targeted iron nanoparticles with platinum-(IV) prodrugs and anti-EZH2 siRNA show great synergy in combating drug resistance in vitro and in vivo.
Yu C; Ding B; Zhang X; Deng X; Deng K; Cheng Z; Xing B; Jin D; Ma P; Lin J
Biomaterials; 2018 Feb; 155():112-123. PubMed ID: 29175080
[TBL] [Abstract][Full Text] [Related]
18. Platinum anticancer drugs. From serendipity to rational design.
Monneret C
Ann Pharm Fr; 2011 Nov; 69(6):286-95. PubMed ID: 22115131
[TBL] [Abstract][Full Text] [Related]
19. Layer-by-layer nanoparticles co-loading gemcitabine and platinum (IV) prodrugs for synergistic combination therapy of lung cancer.
Zhang R; Ru Y; Gao Y; Li J; Mao S
Drug Des Devel Ther; 2017; 11():2631-2642. PubMed ID: 28919713
[TBL] [Abstract][Full Text] [Related]
20. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
